BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Kidney cancer (RCC) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for renal cell carcinoma: 182 (132 sponsors; 17 newly posted in the last 180 days, 9 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 6, rank 86 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 75, Phase 2 60, Phase 3 20, Phase 4 0, N/A 25.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Merck Sharp & Dohme LLC MRK12P3 7, P2 4, P1 101
Exelixis EXEL6P3 3, P1 312
Bristol-Myers Squibb BMY7P1 2, NA 1, P2 2, P3 211
AstraZeneca AZN6P2 1, P3 2, P1 2, NA 102
Telix Pharmaceuticals (Innovations) Pty Limited TLX4P3 2, P2 1, P1 110
Arcus Biosciences, Inc. RCUS3P3 1, P1 200
EMD Serono Research & Development Institute, Inc.2P1 1, P3 101
Eisai Inc.1P3 100
Xynomic Pharmaceuticals, Inc.1P3 101
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4P2 2, P1 202
Regeneron Pharmaceuticals REGN4P2 410
A2 Biotherapeutics Inc.3NA 2, P2 100
GI Innovation, Inc.3P2 301
Sichuan Baili Pharmaceutical Co., Ltd.3P1 2, P2 101
Elephas2NA 201
Eli Lilly and Company LLY2P1 202
HiFiBiO Therapeutics2P1 202
Ipsen2NA 201
Jiangsu Hansoh Pharmaceutical Co., Ltd.2P2 1, P1 100
23andMe, Inc.1P2 100
3D Medicines (Sichuan) Co., Ltd.1P2 101
7 Hills Pharma, LLC1P2 100
AccSalus Biosciences, Inc.1P1 100
Actuate Therapeutics Inc. ACTU1P2 100
Adela, Inc1NA 101

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P23D Medicines (Sichuan) Co., Ltd.NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsSolid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinomarecruiting170
2026-12-15 est.P3Exelixis EXELNCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNon-Clear Cell Renal Cell Carcinomaactive not recruiting317
2026-12-22 est.P1/P2Merck Sharp & Dohme LLC MRKNCT05468697 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LIRenal Cell Carcinomaactive not recruiting60
2026-12-30 est.P3Xynomic Pharmaceuticals, Inc.NCT03592472 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Renal Cell Carcinomarecruiting413
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2Arsenal Biosciences, Inc.NCT06245915 AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)Advanced/Metastatic Clear Cell Renal Cell Carcinoma; Recurrenceactive not recruiting37
2026-12-31 est.P2Imbioray (Hangzhou) Biomedicine Co., Ltd.NCT07087158 A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaRenal Cell Carcinoma (RCC)recruiting30
2027-02 est.P1/P2Beijing Scitech-Mq Pharmaceuticals LimitedNCT06127238 Study of ST-1898 in Advanced Renal Cell CarcinomaAdvanced Renal Cell Carcinomaactive not recruiting90
2027-02 est.P1/P2GI Innovation, Inc.NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNSrecruiting102

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-28 est.P3Merck Sharp & Dohme LLC MRKNCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post NephrecCarcinoma, Renal Cellactive not recruiting1800
2026-10-05P2Hoffmann-La RocheNCT05805501 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomRenal Cell Carcinomacompleted199
2026-08-28P2/P3Hutchmed HCMNCT05522231 Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Advanced Renal Cell Carcinomacompleted265
2026-08-10P1/P2Merck Sharp & Dohme LLC MRKNCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Carcinoma, Renal Cellcompleted393
2026-07-23P1/P2Merck Sharp & Dohme LLC MRKNCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Carcinoma, Renal Cellcompleted263
2026-07-01 est.P1/P2Scancell Ltd SCNLDNCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerTriple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamousrecruiting168
2026-06-30 est.P3Telix Pharmaceuticals (Innovations) Pty Limited TLXNCT06750419 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyClear Cell Renal Cell Carcinomarecruiting82
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "renal cell carcinoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.